We are thrilled to announce that Euroeyes Clinicgroup has, for 8 consecutive years, been the leading clinic Group of treatments of presbyopia and Trifocal lens implantations worldwide. Remarkably, over 95% of these implants have been AcriLisa lenses, both toric and non-toric, from Carl Zeiss.

As a market leader in Presbyopia treatment, EuroEyes has rigorously tested various lenses over the years. However, we consistently return to AcriLisa Tri, adhering to the principle of “do not changing a winning horse.” After more than 8 years, these lenses have demonstrated exceptional sustainability and long-term safety, reaffirming our confidence in their efficacy.

Furthermore, it’s worth noting that no other lens on the market has demonstrated the same level of long-term sustainability as the AcriLisa Trifocal Lens from Carl Zeiss.

While numerous healthcare companies have introduced new lenses to the market, most have withdrawn them after just a few years. Dr. Joergensen emphasizes, “Implanting over 10,000 lenses annually of a single type put a lot of pressure on me and the company doing the right thing, however with over 95 % patient satisfaction, underscores our unwavering commitment to patient care.”

We are proud to continue leading the way in providing high-quality, reliable Trifocal lens solutions to our patients, ensuring their long-term visual health and satisfaction.